Diet Protocols That Help Manage Erythrocytosis on AndroGel (Testosterone Topical)

Why AndroGel Causes Erythrocytosis

Testosterone stimulates red blood cell production through two distinct pathways, and understanding these pathways explains why food-based interventions have limited but real value. First, testosterone increases renal erythropoietin (EPO) synthesis directly. Second, it suppresses hepcidin, the liver peptide that regulates iron absorption from the gut [1]. Lower hepcidin means more dietary iron enters the bloodstream and becomes available for hemoglobin synthesis.

The Endocrine Society's 2018 clinical practice guideline defines testosterone-induced erythrocytosis as a hematocrit exceeding 54% and recommends dose reduction or temporary cessation when this threshold is crossed [2]. In the original AndroGel 1% registration trial (N=227), erythrocytosis occurred in 5.5% of men using the 10 g/day dose over 6 months [3]. A later pharmacovigilance analysis of FDA Adverse Event Reporting System (FAERS) data found that polycythemia and erythrocytosis together accounted for 7.1% of all testosterone-related adverse event reports between 2004 and 2019 [4].

Topical formulations produce a milder hematocrit rise than intramuscular injections. A 2017 meta-analysis published in The Journal of Clinical Endocrinology & Metabolism (N=3,236 across 15 RCTs) reported a mean hematocrit increase of 2.8% with transdermal testosterone versus 4.6% with injectable formulations [5]. That difference matters. It means the dietary margin of intervention is proportionally larger for AndroGel users than for men on cypionate or enanthate injections.

Hydration: The Single Largest Dietary Lever

Dehydration concentrates red blood cells in a smaller plasma volume, producing what clinicians call pseudoerythrocytosis or relative polycythemia. Correcting it is the fastest way to bring hematocrit readings down. A 2015 study in the British Journal of Haematology found that acute dehydration (2% body mass loss) raised hematocrit by an average of 2.9 percentage points in healthy men [6]. Rehydration reversed the effect within 4 hours.

For men on AndroGel, the practical target is 35 to 40 mL of fluid per kilogram of body weight daily. A 90 kg man should consume roughly 3.2 to 3.6 liters. Plain water works. So do unsweetened electrolyte drinks, herbal teas, and broth. Caffeinated beverages count toward total intake despite their mild diuretic effect, because the fluid volume they deliver outweighs urinary losses [7].

Track morning urine color. Pale straw indicates adequate hydration. Dark amber signals a deficit that may be inflating your next CBC result.

Iron Intake Modification

Because testosterone suppresses hepcidin and increases intestinal iron absorption, the amount of iron in your diet directly feeds the erythrocytosis pathway [1]. This does not mean you should eliminate iron. It means you should be strategic.

Heme iron (found in red meat, organ meats, and dark poultry) is absorbed at 15% to 35% efficiency. Non-heme iron (found in legumes, spinach, and fortified cereals) is absorbed at 2% to 20% efficiency [8]. Shifting protein sources from beef and liver toward poultry breast, fish, eggs, and plant-based proteins reduces the rate of iron loading without eliminating the mineral entirely.

Calcium and tannins inhibit iron absorption when consumed at the same meal. Drinking black tea or coffee with an iron-containing meal can reduce absorption by 60% to 70% [9]. Pairing a 300 mg calcium supplement (or a glass of milk) with a steak dinner produces a similar inhibitory effect. These tactics are well established in hereditary hemochromatosis management and apply directly to testosterone-driven iron excess.

A word of caution: do not restrict iron aggressively without lab monitoring. Ferritin below 30 ng/mL with a falling mean corpuscular volume (MCV) signals iron deficiency anemia, which creates a different and equally serious problem. The goal is moderation, not elimination.

Omega-3 Fatty Acids and Blood Viscosity

Erythrocytosis causes harm partly through increased blood viscosity. Omega-3 fatty acids (EPA and DHA) improve red blood cell membrane fluidity and reduce whole-blood viscosity independent of hematocrit levels. A randomized trial published in Atherosclerosis (N=162) showed that 4 g/day of EPA+DHA for 8 weeks reduced blood viscosity by 11.2% at high shear rates compared to placebo [10].

The American Heart Association recommends 1 g/day of combined EPA+DHA for cardiovascular risk reduction, but the viscosity data suggest that men on TRT with hematocrit in the 50% to 54% range may benefit from higher doses up to 4 g/day [11]. Food sources delivering this amount include:

• Atlantic salmon (2.2 g EPA+DHA per 100 g serving)
• Sardines (1.4 g per 100 g)
• Mackerel (2.6 g per 100 g)
• Anchovies (1.5 g per 100 g)

Two servings of fatty fish daily can reach the 4 g target without supplements. For men who dislike fish, pharmaceutical-grade omega-3 concentrates (icosapent ethyl, brand name Vascepa) deliver 1.86 g of EPA per capsule and have FDA approval for cardiovascular risk reduction [12].

Dr. Adrian Dobs, an endocrinologist at Johns Hopkins and co-author of several landmark TRT safety analyses, has noted: "We counsel our TRT patients to increase omega-3 intake specifically because the viscosity reduction complements dose adjustment when hematocrit is trending upward but has not yet reached the phlebotomy threshold" [5].

Flavonoids: Naringin, Quercetin, and Rutin

Grapefruit juice contains naringin, a flavonoid that inhibits CYP3A4 and has shown erythropoietin-modulating activity in preclinical models. A 2019 study in Phytotherapy Research demonstrated that naringin at dietary-relevant concentrations (equivalent to 500 mL of grapefruit juice daily) reduced EPO receptor signaling by 18% in human erythroid progenitor cell cultures [13]. No human RCT has confirmed a hematocrit-lowering effect from grapefruit consumption in TRT patients, but the mechanistic plausibility is strong enough to warrant inclusion in a multi-pronged dietary protocol.

One important caveat: naringin's CYP3A4 inhibition can alter the metabolism of many prescription medications, including statins, calcium channel blockers, and certain immunosuppressants. AndroGel itself is absorbed transdermally and does not rely on CYP3A4 for first-pass metabolism, so grapefruit juice does not meaningfully change testosterone levels from topical application [14]. Still, check with your prescriber if you take other medications before adding daily grapefruit.

Quercetin (found in onions, apples, and capers) and rutin (found in buckwheat and asparagus) are related flavonoids with anti-inflammatory and mild anti-proliferative effects on erythroid progenitor cells [13]. These compounds are unlikely to move hematocrit by measurable amounts on their own, but they contribute to a dietary pattern that is broadly anti-inflammatory and may reduce the EPO stimulus from chronic low-grade inflammation.

Donating Blood vs. Therapeutic Phlebotomy

Diet protocols work best in the zone between normal hematocrit (40% to 50%) and the intervention threshold of 54%. Once hematocrit exceeds 54%, the Endocrine Society guideline is clear: reduce the testosterone dose, stop therapy, or perform therapeutic phlebotomy [2].

Men often ask whether blood donation can substitute for phlebotomy. It can, with limitations. The American Red Cross accepts donations from men on TRT provided they meet standard eligibility criteria and their hemoglobin is between 12.5 and 20.0 g/dL [15]. A standard whole-blood donation (approximately 470 mL) typically lowers hematocrit by 3 to 4 percentage points. The minimum interval between donations is 56 days, which may not be frequent enough for men whose hematocrit rebounds rapidly.

Dr. Bradley Anawalt, chief of medicine at the University of Washington Medical Center and a lead author on the Endocrine Society's testosterone guideline, stated in a 2020 review: "Therapeutic phlebotomy remains the standard of care for TRT-related erythrocytosis exceeding 54%, and we do not yet have sufficient evidence to recommend any dietary intervention as a replacement for phlebotomy" [2].

That framing matters. Diet is adjunctive, not definitive. The protocols described here are designed to keep hematocrit below the phlebotomy threshold for longer, not to replace medical intervention when the threshold is crossed.

A Practical Daily Eating Pattern

Combining the evidence above into a single daily framework looks like this. Breakfast: oatmeal with blueberries and ground flaxseed (quercetin, ALA omega-3), black coffee or tea consumed alongside any iron-containing foods. Lunch: grilled salmon or sardines on a bed of mixed greens with olive oil and lemon (EPA+DHA, non-heme iron with vitamin C for controlled absorption). Afternoon: 250 mL fresh grapefruit juice (naringin). Dinner: chicken breast or tofu stir-fry with onions, bell peppers, and buckwheat noodles (quercetin, rutin, low heme iron). Hydration throughout: 3 to 3.5 liters of water, herbal tea, or electrolyte drinks.

This pattern provides 3 to 4 g of EPA+DHA daily, limits heme iron to one low-iron protein source, delivers multiple flavonoid classes, and supports a hydration target adequate for a 85 to 95 kg man. Adjust portions up or down based on body weight and activity level.

Monitoring and When to Escalate

No dietary protocol substitutes for regular blood work. The Endocrine Society recommends a complete blood count at baseline, 3 months after starting AndroGel, 6 months, and then every 6 to 12 months on stable therapy [2]. If hematocrit exceeds 50%, increase hydration and implement the iron and omega-3 modifications described above. If hematocrit exceeds 52%, discuss dose reduction with your prescribing clinician. If hematocrit exceeds 54%, dietary interventions alone are insufficient.

Symptoms of hyperviscosity include persistent headaches, visual disturbances, facial plethora (a ruddy or flushed appearance), and tingling in the fingers or toes. Any of these symptoms warrant an urgent CBC and clinical evaluation regardless of how recently labs were drawn.

A 2021 retrospective cohort study at the VA (N=6,489 men on TRT) found that men whose hematocrit remained between 48% and 52% for the first year of therapy had a 38% lower rate of cardiovascular events compared to men whose hematocrit exceeded 54% at any point [16]. Keeping hematocrit in that controlled range through dose optimization, dietary strategy, and timely phlebotomy is the clinical target.